Watch for topline data from ATR-04 Cohort 1 and initial ATR-COSF cosmetic study results, both expected by year-end 2026. Positive data could trigger the additional $5.25M-$10.5M investment from institutional investors, extending the cash runway.
Drugs in focus
AZTR drug pipeline →ATR-04
◆ Mixed Named in this press release- Impact
- Phase
- Phase 1/2
- Time to market
- Unknown — at least 3-5 years if Phase 1/2 data is positive, followed by Phase 3 trials and FDA review. The Fast Track designation could accelerate the timeline.
- Next catalyst
- None dated
What to watchWatch for ATR-04 Phase 1/2 first-cohort topline data expected Q4 2026, positive safety/efficacy signals could drive a sharp rally given the tiny market cap, but the ~6-month cash runway means a dilutive financing is likely before year-end regardless of results. The stock is a high-risk binary play on a single early-stage asset.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 13 $0.6084entry
- T+1 · yesterday +3.06%α +4.97% · $0.6270
- T+2 · todayOpen
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Azitra reported a Q3 2026 net loss of $3.0M ($0.29 per share), wider than the $2.8M loss a year ago, with cash of $3.8M. The key catalysts are upcoming topline data from the ATR-04 Phase 1/2 trial (Cohort 1) and initial results from the ATR-COSF first-in-human cosmetic study, both expected by year-end 2026. The company also noted that institutional investors may invest an additional $5.25M to $10.5M after the ATR-COSF results are announced.
Key Financial Metrics
Key Facts
- Net loss of $3.0M for Q3 2026, compared to $2.8M in Q3 2025
- Cash and cash equivalents of $3.8M as of September 30, 2026
- ATR-04 Phase 1/2 trial completed Cohort 1; safety committee recommended proceeding to Cohort 2
- Topline data from ATR-04 Cohort 1 expected in Q4 2026
- First-in-human cosmetic study of ATR-COSF planned with initial results expected by year-end 2026
- Institutional investors may invest an additional $5.25M to $10.5M after ATR-COSF results are announced
Financial Impact
Net loss increased $0.2M year-over-year; cash burn rate suggests runway of approximately 3-4 quarters at current spending levels
Risk Factors
- Cash and cash equivalents of $3.8M may not be sufficient to fund operations beyond mid-2027 without additional financing
- Clinical-stage company with no approved products or revenue; results from ex vivo studies may not translate to human trials
- Potential dilution from exercise of financial instruments issued in the March 2026 private placement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302938286 |
Track record
16 reports on AZTR
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.73% at T+60 after the May 21, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13D Neutral 5/10 Entry $0.5805 Now $0.6090 +4.91% settles Feb 16
- Nov 12, 20264d ago Press Release Neutral 4/10 Viewing Entry $0.6084 Now $0.6090 +0.10% settles Feb 11
- Nov 12, 20264d ago 8-K Neutral 4/10 No price data
- Nov 12, 20265d ago SC 13G/A Neutral 2/10 Entry $0.6685 Now $0.6090 −8.90% settles Feb 10
- Nov 10, 20267d ago 8-K Neutral 3/10 Entry $0.6000 Now $0.6090 +1.50% settles Feb 8
- Nov 10, 20267d ago Press Release Neutral 3/10 Entry $0.6000 Now $0.6090 +1.50% settles Feb 8
- Oct 29, 202619d ago 8-K Neutral 3/10 Entry $0.7571 Now $0.6090 −19.56% settles Jan 27
- Oct 26, 202622d ago 8-K Neutral 4/10 Entry $1.53 Now $0.6090 −60.20% settles Jan 22
- Oct 22, 202626d ago 8-K Neutral 3/10 Entry $0.0715 Now $0.6090 +751.75% settles Jan 21
- Oct 1, 20266w ago 8-K Neutral 4/10 Entry $0.1285 Now $0.6090 +373.93% settles Dec 28
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers